MedTrace Logo

Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis

NCT02694393 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-06-24

Study results available
· View outcomes & findings →

Summary

This study will assess the safety of inhaled sodium nitrite in adults with Cystic Fibrosis and chronic Pseudomonas infections, and determine the ability of sodium nitrite to reduce the burden of Pseudomonas.

Conditions

Interventions

DRUG

sodium nitrite

inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization

Sponsors & Collaborators

  • Mast Therapeutics, Inc.

    collaborator INDUSTRY

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • Schmidhofer, Mark, MD

    lead INDIV

Principal Investigators

  • Joseph Pilewski, MD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2022-07-21
Completion
2022-07-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02694393 on ClinicalTrials.gov